Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics.

1. Opioids Market to
2018 - Increasing
Concentration of
Abuse-Resistant
Branded Generics
Alter Competitive
Dynamics in this
Flat Market

2. World's Fastest Growing Market Description
Research Reports Collection.
Leading business intelligence provider GBI Research has released its
latest research report, entitled “Opioids Market to 2018 - Increasing
Concentration of Abuse-Resistant Branded Generics Alter Competitive
Dynamics in this Flat Market”. The current opioids market is
characterized by a very broad and highly diversified product portfolio.
Patients experiencing moderate to severe pain for a range of
underlying physiological reasons are virtually exclusively treated with
opioid analgesics. As a result, most patient populations experiencing
more severe levels of pain across most pain indications, with the
exception of, for example, migraines, are heavily dominated by
opioids. As a therapeutic drug class, opioids have virtually no
competition from molecules with non-opioid receptor targets.
However, although the competition is virtually exclusively limited to
opioid compounds, the current environment within this therapeutic
class is highly competitive and strongly diversified. The approved
drugs are based on 16 different opioid compounds and are
differentiated on a range of characteristics, which include dosage,
route of administration and pharmacokinetic features, as well as
increasingly on the basis of abuse-resistance technologies.
To know more about this reports, please visit @ http://www.researchmoz.us/opioids-market-to-2018-increasing-
concentration-of-abuse-resistant-branded-generics-alter-competitive-dynamics-in-this-flat-market-report.html

3. Whilst the prescription rates of opioid analgesic have seen a historically
unprecedented increase over the last two decades, particularly in the
US, this has resulted in a dramatic concomitant increase in opioid abuse
and dependency. Over the last few years, the growing concern over
opioid abuse has resulted in tighter regulations and increasingly vocal
concerns by physicians. Due to these concerns from regulatory
authorities and physicians about growing opioid abuse, there has been a
seismic shift towards developing abuse-resistant formulations of
extended-release opioid analgesics, including both novel products and
reformulations of existing ones. Since the launch of the first abuse-
resistant product, Embeda, in 2009, a whole range of novel products and
reformulations of existing product ranges have been brought to the
market. While abuse-resistant formulations do not confer any clinical
benefits, they have become an essential differentiating factor in the
current market environment in order ensure that products remain
competitive for the future. There is a growing concentration and
competition among abuse-resistant products, which is expected to be
the primary driving factor in this largely stagnant market, particularly as
the current developmental pipeline is very small and is characterized by
a lack of innovation, with virtually no novel compounds and strong
saturation across multiple pain indications.
To know more about this reports, please visit @ http://www.researchmoz.us/opioids-market-to-2018-increasing-
concentration-of-abuse-resistant-branded-generics-alter-competitive-dynamics-in-this-flat-market-report.html

4. Scope
• An overview of the current opioid product market.
• A brief discussion about the inconsistent prescription preferences
among European physicians.
• A brief profile of the most important opioid products.
• A pipeline analysis of the opioid products currently in development
and an overview of the developmental pipeline by phase, by the route
of administration and a summary of the promising pipeline products.
• An overview of the M&A and licensing deals, as well as co-
development deals, across multiple indications in which opioids are
frequently used in patients suffering from moderate to severe pain.
Reasons To Buy
• Identify trends in the developmental pipeline for opioid analgesics.
• Develop their awareness of the regulatory environment, physician
concerns and inconsistency of prescription preferences among
physicians.
To know more about this reports, please visit @ http://www.researchmoz.us/opioids-market-to-2018-increasing-
concentration-of-abuse-resistant-branded-generics-alter-competitive-dynamics-in-this-flat-market-report.html

5. Table Of Contents :
• Introduction
• Overview of Currently Marketed Products
• Pipeline Analysis
• Deals Analysis
• Appendix
Find All Latest published Market Research Reports @
http://www.researchmoz.us/report.html
To know more about this reports, please visit @ http://www.researchmoz.us/opioids-market-to-2018-increasing-
concentration-of-abuse-resistant-branded-generics-alter-competitive-dynamics-in-this-flat-market-report.html

6. World's Fastest Growing Market
Research Reports Collection. Contact Us :
Contact: Mrs.Sheela AK
• Tel:+1-518-618-1030
• Toll Free: 866-997-4948
• State Tower
• 90 State Street, Suite 700
• Albany, NY 12207
• United States
Email: sales@researchmoz.us
To know more about this reports, please visit @ http://www.researchmoz.us/opioids-market-to-2018-increasing-
concentration-of-abuse-resistant-branded-generics-alter-competitive-dynamics-in-this-flat-market-report.html